FDA Approval of Keytruda® in Head and Neck Cancer Highlights Potential for Gedeptin® Combination Therapy

The recent FDA approval of Keytruda® (pembrolizumab) for resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) has significant implications for the treatment landscape, particularly for GeoVax Labs, Inc.'s Gedeptin® development program. This approval marks a pivotal advancement in curative-intent therapy for HNSCC, aligning with GeoVax's strategy to combine Gedeptin® with checkpoint inhibitors like pembrolizumab to improve outcomes.

GeoVax plans to initiate a Phase 2 clinical trial in 2026, evaluating Gedeptin® in combination with a checkpoint inhibitor for patients with locally advanced HNSCC scheduled for surgery. The trial will focus on enhancing tumor clearance and reducing relapse by leveraging Gedeptin®'s targeted cytotoxicity alongside the systemic immune activation provided by checkpoint inhibition. This approach is supported by findings published in the New England Journal of Medicine, which highlight the benefits of PD-1 inhibition in the curative setting for HNSCC.

David Dodd, GeoVax's Chairman and CEO, emphasized the significance of this development, stating that the combination of Gedeptin® therapy with pembrolizumab could enhance local tumor eradication and systemic anti-tumor immunity. Dr. Kelly McKee, GeoVax’s Chief Medical Officer, added that Gedeptin's tumor-targeted cytotoxicity could improve immunotherapy efficacy, especially in the perioperative window, marking an exciting phase in Gedeptin's development.